Immune cell therapy for advanced mesothelioma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new type of immune cell therapy made from donor cells that are trained to target two specific proteins found on mesothelioma tumors. The goal is to see if these cells can safely shrink tumors or slow the disease when given directly into the chest or belly area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of mesothelioma that cannot be removed with surgery, or has come back or spread.
- You must have tried at least one standard treatment, or your doctor has said you cannot or should not take standard therapy.
- Your tumor must have certain proteins (MSLN and FAP) that the new cells are designed to attack.
- You must be in generally good health (able to care for yourself and do light activities).
- You must not have serious infections, uncontrolled heart or lung problems, or other major health issues that would make the treatment risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding cadonilimab (an immune treatment) and bevacizumab (a medicine that targets blood supply to tumors) to standard chemotherapy can control pleural malignant mesothelioma that cannot be removed with surgery. It’s meant for people who have not yet started medicine for advanced disease and who meet health and blood test requirements.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial tests adding a drug called fianlimab to another drug (cemiplimab) plus chemotherapy for people with a type of lung cancer called pleural mesothelioma. It aims to see if the combination is more effective than cemiplimab plus chemo alone.
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
Hear when a new Malignant Pleural Mesotheliomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.